Published : 29 May 2014, 09:36 AM
Updated : 08 Aug 2022, 06:49 PM
Neither GlaxoSmithKline nor the fraud office provided further details about what practices were being investigated, says the 'New York Times'.
“GSK is committed to operating its business to the highest ethical standards and will continue to cooperate fully with the S.F.O.,” the company said in a statement.
Britain and the United States have strict laws prohibiting payments to government officials in order to gain an advantage over other competitors.
The fraud office is investigating Glaxo’s business activities in “multiple jurisdictions,” according to a person familiar with the investigation who was not authorised to speak publicly.
The Chinese authorities have been investigating the drugmaker’s business practices related to payments to doctors and other health care professionals since last year and questions have been raised in recent months about the company’s practices in Iraq and Poland.
This month, the Chinese authorities accused Mark Reilly, the former head of Glaxo’s operations in China, of ordering employees to bribe doctors and other hospital staff to use the drug maker’s products, resulting in more than $150 million in illegal revenue. Two other Chinese-born Glaxo executives were also charged in the matter.
Reilly, a Briton, stepped down as Glaxo’s top executive in China last year when the Chinese authorities opened the investigation into the potential corruption.
“Certain senior executives of GSK China who know our systems well, appear to have acted outside of our processes and controls which breaches Chinese law,” Glaxo said in July, after meeting with the Chinese authorities. “We have zero tolerance for any behaviour of this nature.”
Major European and American drugmakers have opened research centres and hired sales agents in China in recent years to bolster their presence in what many think will soon be the world’s second-largest pharmaceutical market, behind the United States and ahead of Japan.
But as foreign drugmakers have rushed to gain market share, Beijing has increasingly pressed multinational companies on their pricing strategies.
The Chinese authorities have said that Glaxo compensated doctors for travel to conferences and lectures that never took place. They have also accused Glaxo of inflating drug prices in China.
In December, Glaxo announced that it was changing its worldwide compensation system for sales staff who work with healthcare professionals. The drugmaker also said that it would stop paying doctors to promote its products.